Get the Stockscreener App
7.68
1.92%
-0.15
Zevra Therapeutics Inc stock is traded at $7.68, with a volume of 326.55K.
It is down -1.92% in the last 24 hours and down -5.77% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$7.83
Open:
$7.94
24h Volume:
326.55K
Relative Volume:
0.70
Market Cap:
$409.93M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-5.9535
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-4.83%
1M Performance:
-5.77%
6M Performance:
+1.99%
1Y Performance:
+13.27%
1-Day Range:
$7.635
$8.01
1-Week Range:
$7.635
$8.08
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.68 | 409.93M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra therapeutics CFO sells shares for $86,471 - MSN
Zevra Therapeutics exec sells $23,587 in stock - MSN
Neil F. Mcfarlane Sells 61,273 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni Sells 3,000 Shares - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO Sells $86,460.00 in Stock - MarketBeat
Zevra Therapeutics exec sells $23,587 in stock By Investing.com - Investing.com Australia
Zevra therapeutics executive Joshua Schafer sells $82,526 in stock By Investing.com - Investing.com Australia
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Brokers Issue Forecasts for ZVRA FY2029 Earnings - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Zevra Therapeutics CEO Neil McFarlane sells $727,389 in stock By Investing.com - Investing.com Canada
KemPharm Stock: Insider Sales Amid Strong Market Performance - sharewise
Zevra therapeutics CFO sells shares for $86,471 By Investing.com - Investing.com Nigeria
Zevra Therapeutics CEO Neil McFarlane sells $727,389 in stock - Investing.com India
Zevra therapeutics executive Joshua Schafer sells $82,526 in stock - Investing.com
Roth Capital Issues Optimistic Forecast for ZVRA Earnings - Defense World
Roth Capital Predicts Higher Earnings for Zevra Therapeutics - MarketBeat
(ZVRA) Investment Analysis - Stock Traders Daily
What is Roth Capital’s Forecast for ZVRA FY2029 Earnings? - Defense World
Stratos Wealth Partners LTD. Decreases Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
2 ‘Strong Buy’ Growth Stocks Poised For 141% To 193% Gains, According To Wall Street - Barchart
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street - MSN
Hypersomnia Pipeline 2024: MOA, ROA, and Clinical Trial - openPR
BlackRock, Inc. Increases Stake in Zevra Therapeutics Inc. - GuruFocus.com
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Janney Montgomery Scott LLC Has $2.48 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy” - Defense World
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - GlobeNewswire
Breakthrough Treatment for Rare Brain Disease: Zevra's MIPLYFFA Earns Major Industry Recognition - StockTitan
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Rare Disease Leader Zevra Takes Center Stage at Major Healthcare Investment Events - StockTitan
Cantor Fitzgerald Predicts ZVRA FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ZVRA FY2025 Earnings - MarketBeat
Objective long/short (ZVRA) Report - Stock Traders Daily
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $21.57 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts - Defense World
Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock - Yahoo Finance
Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings - Defense World
Learn to Evaluate (ZVRA) using the Charts - Stock Traders Daily
FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald - Defense World
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schafer Joshua | CCO & EVP, Bus. Development |
Feb 13 '25 |
Sale |
7.86 |
10,500 |
82,527 |
29,486 |
| Clifton R. LaDuane | CFO & Treasurer |
Feb 13 '25 |
Sale |
7.86 |
11,000 |
86,471 |
51,361 |
| McFarlane Neil F. | President and CEO |
Feb 13 '25 |
Sale |
7.86 |
61,273 |
481,428 |
222,060 |
| McFarlane Neil F. | President and CEO |
Feb 14 '25 |
Sale |
8.05 |
30,544 |
245,962 |
191,516 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):